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Abstract
Expert consensus-based recommendations regarding key issues in the use of primary (or neoadjuvant) systemic 
treatment (PST) in patients with early breast cancer are a valuable resource for practising oncologists. PST remains a 
valuable therapeutic approach for the assessment of biological antitumor activity and clinical efficacy of new treatments 
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in clinical trials. Neoadjuvant trials provide endpoints, such as pathological complete response (pCR) to treatment, that 
potentially translate into meaningful improvements in overall survival and disease-free survival. Neoadjuvant trials need 
fewer patients and are less expensive than adjuvant trial, and the endpoint of pCR is achieved in months, rather than 
years. For these reasons, the neoadjuvant setting is ideal for testing emerging targeted therapies in early breast cancer. 
Although pCR is an early clinical endpoint, its role as a surrogate for long-term outcomes is the key issue. New and 
better predictors of treatment efficacy are needed to improve treatment and outcomes. After PST, accurate management 
of post-treatment residual disease is mandatory. The surgery of the sentinel lymph-node could be an acceptable option 
to spare the axillary dissection in case of clinical negativity (N0) of the axilla at the diagnosis and/or after PST. No data 
exists yet to support the modulation of the extent of locoregional radiation therapy on the basis of the response attained 
after PST although trials are underway.
Primary (or neoadjuvant) systemic therapy (PST) has become a 
widely accepted choice to treat patients with locally advanced 
and operable breast cancer in routine clinical practice. PST may 
allow many patients with inoperable locally advanced breast 
cancer to become operable and those with large operable tumors 
to become suitable for breast conservation. PST may provide 
early information on treatment induced-antitumor activity 
and may be a useful tool for switching patients from ineffec-
tive therapy (1). Recently the US Food and Drug Administration 
has released a draft Guidance to Industry, outlining a pathway 
to accelerated approval for neoadjuvant breast cancer therapies 
using pathological complete response (pCR) as an endpoint. The 
association between pCR and outcome is clear for chemotherapy 
in triple-negative breast cancer and HER2-targeted agents in 
HER2-positive disease, but might not hold true for other tumor 
subtypes such as luminal cancers.
This neoadjuvant treatment modal has a major role in clini-
cal research since it offers a unique opportunity to evaluate new 
agents and to enable predictive biomarker discovery. The rapid 
assessment of drug efficacy in PST trials could expedite develop-
ment and approval of treatments for early breast cancer.
Despite these advantages, several drawbacks limit the wide-
spread use of PST in routine clinical practice and the generaliz-
ability of the results of PST clinical trials.
To update the role and setting for PST, during “The Fifth 
Symposium on Primary Systemic Therapy in the Management of 
Operable Breast Cancer” held October 5–7, 2013, in Cremona, 
Italy, an expert faculty in the areas of medical oncology, breast 
surgery, radiation oncology, molecular biology, and pathology, 
provided an overview of recent available data from the most rel-
evant studies and prospective clinical trials of PST in patients 
with operable breast cancer. At the conclusion of the congress 
and in the discussion, the panel of experts formulated a declara-
tion of consensus regarding some key issues on the use of PST 
either in routine practice or clinical research.
This consensus was based on the best available evidence as 
presented at the 2013 Cremona meeting and reflected by votes 
recorded for specific questions on selected topics during the fol-
lowing months, according to a modified Delphi process (Table 1). 
The manuscript was subsequently reviewed and approved by all 
members of the Panel.
Patient Assessment Before Neoadjuvant 
Systemic Therapy and Treatment choice
A core biopsy is recommended for histological diagnosis in 
the initial evaluation of a woman with a suspected breast can-
cer, after the appropriate breast imaging study. This enables 
a detailed pathological diagnosis, and clinicians can identify 
patients who may obtain a significant benefit with specific PSTs 
(2). In the Panel’s opinion, core biopsies are essential either to 
confirm malignancy and to assess histological grade. The pre-
treatment biopsy should be tested for hormone receptor (HR) 
status and HER2 status. Cytological examination is acceptable to 
confirm metastatic spread in the axillary lymph nodes.
Breast cancer is a heterogeneous disease as demonstrated 
by microarray-based expression studies. Higher expression of 
proliferation-related genes, and lower expression of estrogen-
related genes are well known to be strong predictors of pCR but 
worse prognosis after neoadjuvant chemotherapy; immune-
related genes and their related protein expression need more 
validation with regards to their role as predictors of pCR (3). 
Moreover, gene expression patterns can identify different 
intrinsic breast cancer subtypes which have a prognostic role 
(4). Distinct molecular subtypes such as luminal A tumors are 
associated with a better prognosis and paradoxically with lower 
rate of pCR following neoadjuvant chemotherapy (5–7).
Recently, a surrogate definition of luminal A-like and luminal 
B-like subtypes has been proposed on the basis of the immu-
nohistochemistry measurement of estrogen receptor, progester-
one receptor, HER2, and Ki67 (8). Patients with tumors classified 
as luminal A-like in the core biopsy have a lower pCR rate after 
PST, and the achievement of pCR in these patients had no prog-
nostic impact (2). The Panelists were uncertain on whether the 
genomic signatures could add clinically useful information 
to standard immunohistochemistry in the selection of those 
patients who are candidates for PST.
Anthracycline-taxane-based chemotherapy is the reference 
regimen both in adjuvant and neoadjuvant settings. However, 
the optimal sequence of the two drugs is uncertain. Recently, 
two trials addressed this issue in the PST setting (9,10). In the 
Neo-tAnGo trial, which recruited 831 patients, paclitaxel admin-
istered for four cycles before standard anthracycline chemo-
therapy (epirubicin plus cyclophosphamide for four cycles) 
achieved a higher pCR rate compared with the reverse sequence 
(pCR rate: 20% vs 15%, P  =  .03), although no difference was 
seen in terms of long-term survival outcomes (9). In the Z1041 
trial, 282 patients with HER2-positive breast cancer were ran-
domly allocated to receive either fluorouracil, epirubicin, and 
cyclophosphamide followed by paclitaxel plus trastuzumab or 
paclitaxel followed by fluorouracil, epirubicin, and cyclophos-
phamide, both combined with trastuzumab. There was no dif-
ference in the pCR rate between the two arms; asymptomatic 
decreases in left ventricular ejection fraction during neoadju-
vant chemotherapy occurred in similar proportions of patients 
in each group (10). The sample size of the study was small, and 
maybe the differences between treatments in terms of cardiac 
tolerability during neoadjuvant treatment might not have been 
evident. However, as the effect at the clinical and pathological 
level was equal between treatments and as the best sequence 
of anthracyclines and taxanes still remain uncertain, due to the 
well reported additive cardiac toxicity, trastuzumab should be 
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Table 1. Summary of most relevant recommendations* 
Levels of recommendations Evidence
A core biopsy is essential for histological diagnosis in the initial 
assessment of a woman with a suspected breast tumor and to 
assess histological grade, HR status, and HER2 status
Prospective cohort studies and 
expert opinion
Cytological examination is acceptable only to verify metastatic 
spread in the axillary lymph nodes
Expert opinion
It is uncertain whether genomic signatures could add clinically 
useful information to standard immunohistochemistry in the 
prediction of patients with higher chance of pathological  
complete response after neoadjuvant chemotherapy
Expert opinion
The best sequence of anthracyclines and taxanes still remain 
uncertain in neoadjuvant setting
Randomized clinical trials and 
expert opinion
Due to its additive cardiac toxicity, trastuzumab should be  
combined with taxanes and not with anthracyclines
Randomized clinical trials and 
expert opinion
Current evidence do not support the addition of antiangiogenic 
agents such as bevacizumab to neoadjuvant chemotherapy
Randomized clinical trials and 
expert opinion
Platinum-based neoadjuvant therapy could be an option for 
triple-negative breast cancer
Randomized clinical trials and 
expert opinion
Dual targeting of HER2 in combination with neoadjuvant  
chemotherapy is an option for HER2-positive disease
Randomized clinical trials and 
expert opinion
Neoadjuvant endocrine therapy is an option in patients with  
HR-positive and HER2-negative breast cancer
Randomized clinical trials and 
expert opinion
pCR do not satisfy the surrogacy criteria of long-term efficacy  
of neoadjuvant chemotherapy in unselected breast cancer
Trial-based meta-analyses of 
randomized clinical trials
pCR can be a valid surrogate of treatment benefit in studies  
recruiting patients with high-risk triple-negative or HER2- 
positive breast cancer
Expert opinion
ER-positive status is a negative predictor factor for pCR in  
HER2-positive breast cancer patients receiving neoadjuvant  
HER2-targeted therapies plus chemotherapy
Randomized clinical trials and 
expert opinion
There is not enough evidence to support the in-course change 
of the initial PST regimen on the basis of the clinical response 
obtained after two chemotherapy cycles, outside a clinical trial
Expert opinion
Ki67 expression measured either after short-term endocrine  
therapy or at posttreatment residual disease following  
neoadjuvant chemotherapy is a valid prognostic parameter, 
and a potential surrogate parameter of endocrine therapy  
efficacy
Prospective cohort studies and 
expert opinion
PEPI score do not provide additional predictive information  
compared with posttreatment Ki67 alone
Expert opinion
MRI is the reference imaging technique for the assessment of 
the extension of residual disease after PST
Expert opinion
None of the imaging techniques available (ie, mammography, 
ultrasound, and FDG PET) provide sufficient accuracy in  
predicting the pathological residual disease
Expert opinion
Residual disease after PST has a prognostic significance Prospective cohort studies and 
expert opinion
No adjuvant chemotherapy is recommended in patients with 
triple-negative breast cancer having a residual disease in  
breast or lymph nodes after a full course of neoadjuvant  
chemotherapy
Expert opinion
There is not enough evidence supporting the omission or  
limitation of RT for women who achieve a pCR after PST
Expert opinion
SLN biopsy after neoadjuvant chemotherapy is an accurate  
method of axillary staging; dual tracer detection and removal  
at least of two SLNs is mandatory to minimize the false-nega-
tive rate of the procedure
Prospective clinical studies and 
expert opinion
*ER = estrogen receptor; FDG = fluorodeoxyglucose; HR = hormone receptor; MRI = magnetic resonance imaging; pCR = pathological complete response, PEPI = preopera-
tive endocrine prognostic index; PET = positron emission tomography; PST = primary (neoadjuvant) systemic therapy; RT = radiotherapy; SLN = sentinel lymph node.
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combined with taxanes and not with anthracyclines to avoid 
any early or late onset possible cardiological complications.
Two randomized studies reported an improvement in pCR 
rate with the addition of the antiangiogenic agent bevacizumab 
to standard neoadjuvant chemotherapy in HER2-negative 
tumors (11,12), but the Panel did not support this combina-
tion in clinical practice, since the higher pCR rate observed 
did not translate into an improved disease-free survival in the 
GeparQuinto trial after a median follow-up of 3.8 years (13).
The potential role for platinum-based chemotherapy in 
triple-negative breast cancer has been evaluated in two pro-
spective randomized trials (GeparSixto and CALGB 40603). 
Preliminary results showed that carboplatin added to a taxane-
anthracycline-based regimen improves the pCR rate compared 
with taxanes and anthracyclines only. The absolute increase of 
the pCR rate in the carboplatin arm was 16% in the GeparSixto 
trial (53% vs 37%; P = .005) (14) and 13% in the CALGB 40603 trial 
(54% vs 41%, odds ratio = 1.71; P = .0029) (15). It is yet unknown 
whether this relatively small improvement in the pCR rate could 
translate into a significant survival benefit in this selected study 
population; however, the panelists concluded that platinum-
based neoadjuvant therapy could be an option for triple-neg-
ative breast cancer when a higher response rate could have an 
impact on the extent of surgery, for example, or when there is 
a poor clinical response to the standard anthracycline-taxane-
based chemotherapy regimen. Moreover, in the triple-negative 
setting, intensified (dose-dense, high-dose) chemotherapy may 
represent another therapeutic option which is currently under 
investigation in prospective trials (16,17).
Information on the germline BRCA mutation status as well as 
on corresponding somatic tumor changes (so-called BRCAness) 
from the GeparSixto trial were not available yet, but this analy-
sis is in progress. BRCA1/2 mutation carriers could represent a 
select population for addition of platinum to standard PST regi-
mens due to the strong biological evidence of high sensitivity of 
BRCA-deficient cells to platinum chemotherapy both in vitro and 
in vivo and high response rates in a nonrandomized prospective 
clinical trials. Long-term survival data and subgroup analyses 
are not yet available in this setting to support a new standard 
regimen for BRCA carriers at this stage; however, this option is 
enticing to consider when data become available, especially in 
BRCA carriers with triple-negative cancers or with poor response 
to after standard neoadjuvant chemotherapy regimens.
Dual targeting of HER2 in combination with neoadjuvant 
chemotherapy is a promising approach for HER2-positive dis-
ease. Prospective randomized studies have demonstrated a 
significant improvement in the rate of pCR with trastuzumab-
based systemic therapy plus either lapatinib or pertuzumab 
(18–20). Moreover, a combined analysis of the neoadjuvant 
GeparQuattro, GeparQuinto, and GeparSixto trials showed that 
HER2-positive breast carcinomas carrying a PIK3CA mutation 
are less likely to achieve a pCR after neoadjuvant anthracycline-
taxane-based chemotherapy plus anti-HER2 treatment, even if 
a dual anti-HER2 treatment is given. Confirmatory data from a 
prospectively designed trial is needed on role of PIK3CA muta-
tion in HER2 signaling before introduction in clinical practice 
(21). Breast-conserving surgery rates were also higher in patients 
treated with these PSTs with an almost 50% conversion rate 
from breast-conserving surgery-ineligible to breast-conserving 
surgery-eligible (22). For that reason, at the time of the meeting, 
most Panelists believed that dual targeting of HER2 is a valid 
option for clinical practice. More recently, both the NeoALLTO 
trial (23) and its parallel study in the adjuvant setting, the ALLTO 
trial, failed to show a significant improvement in long-term 
clinical outcomes in patients receiving dual HER2 inhibition 
with trastuzumab plus lapatinib compared with trastuzumab 
alone. This raises uncertainty about the importance of dual tar-
geting HER2 in neoadjuvant setting particularly if lapatinib is 
added to trastuzumab. It also challenges the utility of relying 
on higher pCR rates in the neoadjuvant setting as surrogates for 
improved long-term outcomes such as disease-free and overall 
survival. With regards to patients with HR-positive and HER2-
positive tumors, the Panel agreed that women with HR-positive 
and HER2-negative tumors may also be candidates for neoadju-
vant chemotherapy, especially in the case of highly proliferat-
ing tumors, such as those classified as luminal B-like. Finally, in 
agreement with the St. Gallen International Expert Consensus 
(8), the Panel supported neoadjuvant endocrine therapy as an 
option in patients with HR-positive and HER2-negative breast 
cancer.
Assessment of Response and Significance 
of pCR
Response evaluation after PST is an important topic: One of 
the major advantages of this treatment modality is in fact to 
obtain a quantifiable evaluation of the sensitivity or resistance 
of any treated patient to a particular treatment or treatment 
combination. As inspired by the I-SPY 2 trial, the potential for 
tumor response (clinical, radiological, or pathological) to predict 
a reduction in micrometastatic burden might allow the individ-
ualization of the proper systemic treatment to administer and 
the rapid assessment of new targeted agents in well-defined 
tumors.
pCR, defined as eradication of invasive tumor from both 
breast and lymph nodes, has been shown to strongly corre-
late with the patient outcome (24). Nevertheless, pCR did not 
satisfy the surrogacy criteria of long-term efficacy of neoadju-
vant chemotherapy at trial-based meta-analysis level in unse-
lected breast cancer patients (24,25). In agreement with the US 
Food and Drug Administration (26), the majority of the Panel 
endorsed pCR as a potential surrogate of treatment benefit 
(to be considered as the primary endpoint) in studies recruit-
ing patients with high-risk triple-negative or HER2-positive 
breast cancer. However, significant variability exists in meth-
ods of pathological assessment of response to PST, and thus 
its interpretation for subsequent clinical decisions. Practical 
methods are needed for standardized evaluation of the post-
PST surgical breast cancer specimen, to promote accurate and 
reliable designation of pCR and meaningful characterization of 
residual disease for clinical trials are needed. The Panel also 
acknowledged that the incomplete characterization of long-
term toxic effects and uncommon adverse events is of concern 
for the accelerated approval of new drugs on the basis of the 
pCR rate.
In HER2-positive tumors, the addition of HER2-directed ther-
apy (ie, trastuzumab) to neoadjuvant chemotherapy improves 
both the rate of pCR or the survival outcomes (27,28). This is 
consistent with the potential surrogate role of pCR for predict-
ing the efficacy of HER2-targeted therapies plus chemotherapy 
in the PST setting. The pCR rate obtained with trastuzumab plus 
chemotherapy is significantly higher in patients with HER2-
positive, HR-negative tumors (50.3%, 95% confidence interval 
[CI]  =  45.0 to 55.5%) compared with those with HER2-positive, 
HR-positive disease (30.9%, 95% CI = 26.3 to 35.8%) (24). Based on 
these data, the Panel concluded that positive estrogen receptor 
(ER) status should be considered a negative predictor for pCR 
in HER2-positive breast cancer patients receiving neoadjuvant 
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HER2-targeted therapies plus chemotherapy. In the neoadju-
vant Herceptin (NOAH) randomized study, women achieving 
pCR after neoadjuvant chemotherapy plus trastuzumab showed 
a better event-free survival as compared with those achieving 
pCR after neoadjuvant chemotherapy alone (hazard ratio = 0.29, 
95% CI  =  0.11 to 0.78, P  =  .0135). This outcome difference was 
not evident in patients not attaining pCR (hazard ratio = 0.92, 
95% CI = 0.61 to 1.39) (28). These findings add complexity to the 
interpretation of the significance of pCR as surrogate for sur-
vival benefit and raise the question as to whether pCR has a 
different prognostic significance depending on the type of treat-
ment applied or the baseline prognosis of the treated population 
(29). The Panel however believed that further confirmation from 
larger datasets is needed before stating that only women attain-
ing a pCR are those destined to obtain a benefit with chemo-
therapy plus HER2-directed therapy.
Whatever its definitive biological and clinical significance, 
pCR is a “late” intermediate endpoint since it can only be 
assessed only at the end of PST. We hypothesize that an even 
earlier surrogate may permit a beneficial in-treatment adjust-
ment to the regimen administered. In an unplanned post hoc 
combined analysis recently published from the GeparTrio trial, a 
clinical response-guided approach—that is, change of the initial 
regimen or not on the basis of the clinical response after two 
chemotherapy cycles—was found superior to the conventional 
approach in terms of disease-free survival (30). Since the evi-
dence is weak, the Panel did not reach a consensus on the reli-
ability of this approach outside of clinical trial.
Several biological markers (assessing apoptosis or prolifera-
tive activity) have been demonstrated to change after PST. Ki67 
is the marker mostly used to assess the proliferative activity 
immunohistochemically and has been extensively studied in 
neoadjuvant endocrine therapy trials as a biomarker of treat-
ment activity and residual risk of relapse and death. In the 
Immediate Preoperative Anastrozole, Tamoxifen, or Combined 
Trial (IMPACT) trial, patients treated with anastrozole had a sig-
nificant suppression of Ki67 level at both 2 and 12 weeks com-
pared with tamoxifen-treated patients. The change of Ki67 levels 
between pretreatment and on-treatment biopsies predicted the 
benefit in disease-free survival observed with anastrozole over 
tamoxifen in the ATAC adjuvant trial (31). A  similar outcome 
prediction was reported for posttreatment Ki67 in the P024 trial, 
which randomly compared letrozole with tamoxifen (32). On the 
basis of the accumulated evidence (31–33), the Panel agreed that 
Ki67 expression measured either after short-term endocrine 
therapy or at posttreatment residual disease is a valid prognos-
tic parameter and a surrogate parameter of endocrine therapy 
efficacy when it is performed in a central laboratory by consist-
ent observers and with established consistency. However, the 
evidence is not strong enough to conclude that early changes 
of Ki67 can help clinicians in the decision-making process of 
changing treatment. The ALTERNATE trial, in which Ki67 level 
at 4 weeks during neoadjuvant endocrine therapy is used to 
select patients that should continue anastrozole or fulvestrant 
from those who should switch to chemotherapy, might provide 
important insight on this topic (34).
The preoperative endocrine prognostic index (PEPI) is a score 
integrating posttreatment Ki67 with ER status (assessed by Allred 
score, 0 or 2 vs 3–8), pathological tumor size and nodal status 
at surgery following 4 months of endocrine therapy. The prog-
nostic role of the PEPI score was assessed in patients enrolled 
in the P024 trial and then validated in the IMPACT dataset (32). 
These data notwithstanding, the Panel was not convinced that 
additional predictive information compared with posttreatment 
Ki67 alone can be obtained by using the PEPI score. A prospec-
tive trial is ongoing to validate PEPI as a prognostic marker after 
neoadjuvant endocrine therapy. This trial assess whether adju-
vant chemotherapy can be spared in patients with PEPI score of 
0 after neoadjuvant endocrine therapy based on their excellent 
prognosis (34).
Ki67 assessed on residual tumor following neoadjuvant 
chemotherapy is a prognostic parameter (35); however, there was 
no consensus among panelists as to whether Ki67 assessed after 
chemotherapy is also a good surrogate of treatment efficacy.
The optimal assessment of residual disease following PST 
is important in assisting in the surgical management of these 
patients with breast cancer. The panel agreed that magnetic 
resonance imaging is the reference imaging technique for the 
assessment of the extension of residual disease after PST. The 
diagnostic role of magnetic resonance imaging could be improved 
by 18fluorodeoxyglucose (FDG) positron emission tomography (36). 
However, in the Panel’s opinion all of the imaging techniques 
available (ie, mammography, ultrasound, and 18FDG-positron 
emission tomography) have limitation in predicting the patho-
logical residual disease. As far as the assessment of tumor shrink-
age after PST is concerned, the accuracy of magnetic resonance 
imaging is clearly superior to mammography; however, only a 
weak superiority over ultrasound and even clinical palpation was 
reported (37). The use of early evaluation of response (eg, after 
1  month or two cycles of treatment) with imaging techniques 
such as magnetic resonance imaging or FDG-positron emission 
tomography is currently under investigation in PST setting as a 
possible early classifier of responders versus nonresponders with 
subsequent changes in systemic treatment.
Management of Patients After Neoadjuvant 
Chemotherapy
Some controversy exists about the postsurgical approach in 
women who have received PST. This is true both for patients 
achieving a pCR and for those with evidence of residual dis-
ease. A  valid tool to predict disease recurrence after primary 
chemotherapy beyond pCR would be helpful in clinical decision 
making. Residual cancer burden index is a validated predictor 
of distant relapse in patients with residual tumor in the sur-
gical specimen (38). The pathological variables included in the 
residual cancer burden index are the bidimensional diameters 
of the primary tumor bed, the proportion of primary tumor area 
containing invasive carcinoma, the number of positive lymph 
nodes, and the diameter of the largest nodal metastasis. Each 
of these parameters was independently associated with distant 
disease-free survival in the developmental cohort of 241 patients 
treated with taxane-anthracycline-based chemotherapy (38). 
Posttreatment Ki67 can also predict the clinical outcomes after 
neoadjuvant chemotherapy, particularly in HR-positive disease 
where the prognostic impact of pCR is limited (35). Although 
eradication of axillary lymph node metastases with neoadjuvant 
chemotherapy was reported being associated with improved 
clinical outcome even in the presence of residual tumor in the 
breast (39), the Panel believed that residual disease in the breast 
still had a prognostic relevance.
Recently, a combined analysis of two NSABP trials with 
a total of 3088 patients showed a lower risk of locoregional 
recurrence in patients responding to neoadjuvant chemother-
apy and not treated with radiotherapy to the chest wall and 
regional lymph nodes (40). Currently, a prospective randomized 
trial (NSABP B-51/RTOG 1304)  addresses the issue of whether 
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locoregional radiotherapy improves the clinical outcomes of 
patients with lymph node-positive breast cancer who become 
lymph node-negative at surgery after PST (41). Pending these 
results, the majority of the Panel did not endorse the omission 
or the limitation of radiotherapy for those women who achieve 
a pCR after PST.
The Panel was uncertain about the optimal management 
of patients with triple-negative breast cancer having a residual 
disease in breast or lymph nodes after a full course of neoadju-
vant chemotherapy with regards to further systemic therapy. No 
recommendations were offered. This unmet clinical need is cur-
rently being addressed in a number of prospective clinical trials 
that are in progress.
Management of Axillary Lymph Nodes
Two important prospective studies assessing the reliability of 
sentinel lymph node (SLN) surgery after neoadjuvant chemo-
therapy were published in 2013 (42,43). This approach has the 
potential advantage of reducing the number of patients who 
require axillary lymph node dissection and the extent of locore-
gional radiotherapy in those who are downstaged by PST. The 
American College of Surgeons Oncology Group (ACSOG) Z1071 
trial prospectively assessed the false-negative rate (FNR) of a 
standardized SLN biopsy procedure in 689 women who con-
verted from clinical node-positive (cN1) to clinical node-nega-
tive (cN0) after neoadjuvant chemotherapy. The SLN detection 
rate was 92.7% (95% CI = 90.5 to 94.6%) and the FNR was 12.5% 
(95% CI  =  9.4 to 16.7%), just above the 10% FNR rate that was 
selected as the primary endpoint (42). The FNR was lower in 
patients for whom both blue dye and radiolabeled colloid were 
used to identify SLN (10.8%), and in patients with more than two 
SLN identified.
The SENTINA trial enrolled patients with both cN0 and cN1 
breast cancer and who were candidates for neoadjuvant chemo-
therapy. The SLN detection rate was quite high before any PST in 
cN0 patients (99.1%) and lower in women who converted from 
cN1 to cN0 (80.1%). In the latter group the FNR was 14.2% (95% 
CI = 9.9 to 19.4%), a value that is less favorable compared with 
the FNR reported in patients who undergo primary surgery (43).
In view of these results, most Panelists considered SLN 
biopsy after neoadjuvant chemotherapy an accurate method 
of axillary staging, but they suggested the use of dual tracer 
and the removal at least of two SLNs to minimize the FNR. 
Conversely, there was no consensus on whether SLN surgery 
could be avoided in the presence of cytologically positive axil-
lary lymph nodes which become negative after PST.
Conclusions
The neoadjuvant approach offers the opportunity to evaluate 
new treatment options in a faster way and with fewer patients 
than large adjuvant trials. New trial designs like window-of-
opportunity trials or postneoadjuvant trials provide a platform 
to identify tumor sensitivity or to overcome tumor resistance at 
an early tumor stages (44). Results from a recent meta-analysis 
questioned the value of pCR after PST as a surrogate endpoint 
of treatment efficacy in patients with “lower-risk” breast can-
cer (25). This may limit the use of PST in operable breast cancer 
in routine clinical practice. However, the PST approach is pre-
ferred for the management of “higher-risk” triple-negative and 
HER2-positive breast cancers where residual disease has a more 
adverse prognosis, and could be advantageous in appropriately 
selected subgroups of patients.
PST remains a potent model for the evaluation of new agents 
and the development of early surrogate markers of response are 
a research priority.
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